You are here

Exondys 51

UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER

UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER

Endpoints

Duchenne Muscular Dystrophy

Sarepta Therapeutics

Flag link:

Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again

Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again

Xconomy

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug

Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug

Endpoints

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal

Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal

Endpoints

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end

Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end

Stat

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Anthem reverses course, agrees to cover Sarepta's Duchenne drug

Anthem reverses course, agrees to cover Sarepta's Duchenne drug

BioPharma Dive

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

3 Biotech Stocks That Could Soar in September

3 Biotech Stocks That Could Soar in September

Motley Fool

PTC Therapeutics

Flag link:

BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta

BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta

Endpoints

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Payor Re-Evaluation On Exondys Positive For Sarepta

Payor Re-Evaluation On Exondys Positive For Sarepta

Yahoo/Benzinga

Duchenne Muscular Dystrophy

Sarepta Therapeutics

Flag link:

Sarepta May Have More Upside After Sales Data

Sarepta May Have More Upside After Sales Data

Seeking Alpha

Duchenne Muscular Dystrophy

Flag link:

Sarepta eyes a different approach to Duchenne: gene therapy

Sarepta eyes a different approach to Duchenne: gene therapy

Bizjournals.com

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

WSJ’s editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters

WSJ’s editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters

Endpoints

Duchenne Muscular Dystrophy

Sarepta Therapeutics

Flag link:

For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51

For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51

Yahoo/Benzinga

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Will Insurers Pay For Sarepta’s DMD Drug?

Will Insurers Pay For Sarepta’s DMD Drug?

Barron's

Duchenne Muscular Dystrophy

Flag link:

Analysts track a payer revolt against Sarepta’s controversial Duchenne drug

Analysts track a payer revolt against Sarepta’s controversial Duchenne drug

Endpoints

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

FDA official warns other drug makers not to copy Sarepta

FDA official warns other drug makers not to copy Sarepta

Stat/Pharmalot

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Major US insurer snubs Sarepta's Duchenne drug

Major US insurer snubs Sarepta's Duchenne drug

BioPharma Dive

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link: